How can PIIINP serve as a biomarker for renal fibrosis?

1. What are the challenges in clinical assessment of renal fibrosis?

Renal fibrosis is a key pathological feature of chronic kidney disease progression, characterized by abnormal deposition of extracellular matrix components such as type I and III collagen. Currently, renal biopsy is the standard method for assessing renal fibrosis, but it has limitations such as sampling errors, procedural risks, and inability for dynamic monitoring. Therefore, developing non-invasive biomarkers for dynamic assessment and monitoring of renal fibrosis has significant clinical importance.

The N-terminal propeptide of type III procollagen (PIIINP) is a metabolic byproduct of type III collagen synthesis, and its level changes can reflect the activity of the fibrotic process. Studies show that type III collagen expression is extremely low in normal kidney tissue but significantly increased in fibrotic kidneys. The PIIINP molecule consists of three identical polypeptide chains with a molecular weight of approximately 42kD and a short half-life, primarily metabolized and degraded in the liver.

2. What is the application value of recombinant rabbit monoclonal antibody against PIIINP in detection?

The recombinant rabbit monoclonal antibody against PIIINP, as an immunodetection tool specifically recognizing PIIINP antigen, has important application value in the diagnosis and monitoring of renal fibrosis. This antibody is prepared by immunizing New Zealand white rabbits and has high affinity and specificity, enabling accurate detection of PIIINP concentration in urine.

In clinical detection applications, this antibody can be used to establish a standardized enzyme-linked immunosorbent assay (ELISA) method for precise measurement of the urine PIIINP/creatinine ratio. Studies show that when using commercial radioimmunoassay kits for detection, the intra- and inter-assay coefficients of variation are 3.2% and 9.5%, respectively, demonstrating good detection stability. Retesting samples after two months of storage showed less than 5% difference, confirming the reliability of the detection method.

In clinical practice, the recombinant rabbit monoclonal antibody against PIIINP helps establish rapid detection platforms to meet the needs of point-of-care testing. Additionally, this antibody can serve as a standard for calibrating detection systems, ensuring comparability of results across different laboratories and providing technical support for standardized assessment of renal fibrosis.

3. What is the correlation between PIIINP and the degree of renal fibrosis?

Clinical studies have confirmed a significant correlation between the urine PIIINP/creatinine ratio and the degree of renal fibrosis. A prospective study involving 199 patients with chronic kidney disease showed that the median urine PIIINP/creatinine ratio in the patient group was 290 ng/mmol, significantly higher than the 93.7 ng/mmol in healthy controls. This difference indicates that elevated PIIINP levels are closely related to renal pathological changes.

Two independent methods were used to assess the degree of renal fibrosis: the BANFF semi-quantitative grading system and a computer-based image analysis system. The results showed that the urine PIIINP/creatinine ratio was significantly positively correlated with the degree of interstitial fibrosis assessed by both methods. Notably, when the ratio exceeded 800 ng/mmol, the negative predictive value for renal biopsy being "non-diagnostic" reached 94%, suggesting that high PIIINP levels may indicate fibrosis severity that significantly affects pathological diagnosis.

4. What factors influence PIIINP levels?

Multivariate analysis showed that estimated glomerular filtration rate (eGFR) and type of kidney disease are independent factors influencing the urine PIIINP/creatinine ratio. As chronic kidney disease stages progress, PIIINP levels tend to increase. Differences exist among different types of kidney diseases, with PIIINP levels in patients with glomerulonephritis being significantly lower than those in patients with tubulointerstitial diseases.

Univariate analysis found that PIIINP levels were positively correlated with serum creatinine and negatively correlated with eGFR, and were associated with age and coronary artery disease. However, no significant correlation was found with factors such as gender, body mass index, hypertension, or diabetes, indicating that PIIINP as a biomarker for renal fibrosis has a certain degree of specificity.

5. What is the clinical significance of PIIINP detection?

Urinary PIIINP detection provides a non-invasive method for assessing renal fibrosis, potentially reducing the need for renal biopsies in some patients. For patients with significantly elevated PIIINP levels, renal biopsy may not provide valuable diagnostic information, and non-invasive monitoring strategies can be considered instead.

Continuous monitoring of PIIINP level changes helps evaluate the effectiveness of anti-fibrotic treatments. Due to the short half-life of PIIINP, its level changes can relatively quickly reflect the effects of therapeutic interventions, providing references for treatment adjustments. This dynamic monitoring capability is an advantage that renal biopsy cannot achieve.

In terms of disease progression prediction, PIIINP levels may serve as a biomarker for assessing the prognosis of chronic kidney disease. High PIIINP levels often indicate active fibrotic processes and are associated with an increased risk of renal function decline, necessitating enhanced clinical monitoring and intervention.

6. What are the future research directions?

Although PIIINP shows promising potential in assessing renal fibrosis, further research is needed to clarify its specificity in various kidney diseases. Larger multicenter studies are required to establish reference ranges for different populations and improve the standardization of detection.

Exploring the combined application value of PIIINP with other fibrosis biomarkers may improve diagnostic accuracy and predictive ability. Studying the dynamic changes of PIIINP in treatment monitoring will provide a basis for optimizing anti-fibrotic treatment regimens.

With the continuous improvement of detection tools such as recombinant rabbit monoclonal antibodies against PIIINP, urinary PIIINP detection is expected to become a routine clinical test, providing strong support for early detection, dynamic monitoring, and treatment evaluation of renal fibrosis, ultimately improving the clinical management of patients with chronic kidney disease.

7. Which manufacturers provide recombinant rabbit monoclonal antibodies against PIIINP?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Recombinant Rabbit Monoclonal Antibody against PIIINP" (product name: PIIINP Recombinant Rabbit mAb (SDT-149-50), a highly specific, sensitive, and stable detection tool for type III collagen synthesis metabolism markers. This product was developed using recombinant rabbit monoclonal antibody technology and has been rigorously validated on multiple platforms, including enzyme-linked immunosorbent assay (ELISA) and Western Blot (WB). It has important application value in fibrosis disease diagnosis, tissue remodeling research, and cardiovascular disease assessment.

Professional Technical Support: We provide detailed product technical documentation, including performance validation data in different sample types, references to clinical correlation studies, and professional application solution recommendations, fully assisting customers in achieving reliable progress in fibrosis research and precision medicine.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. For more details about the "Recombinant Rabbit Monoclonal Antibody against PIIINP" or to request sample testing, please contact us.

Product Information